Sarepta Therapeutics Inc to Present Clinical Update for SRP-5051 Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics Clinical Update MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call and Webcast. (Operator Instructions) As a reminder, today's program is being recorded.
At this time, I'll turn the call over to Doug Ingram, President and CEO, for opening remarks.
Thank you very much for that, and thank you all for joining us this morning.
This morning, we are pleased to report our interim results from MOMENTUM, which is our multi-ascending dose study for our second-generation PPMO RNA therapy, SRP-5051, at 20 mgs per kg.
Now we will be making some statements and potential predictions about the future this morning, so-called forward-looking statements. So please refer to our public filings for a discussion of the inevitable risks and uncertainties that are attendant when one makes forward-looking statements.
And with no further delay, I will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |